Anavex Life Sciences Corp (AVXL)

[falconer66a]

Well, Accept It – Anavex Not (Yet) Newsworthy

Those who have been following the Anavex story; who have investigated and understand its unique and revolutionizing science, anticipate how it will turn out. Eventual authorization to sell Anavex 2-73, which will then provide unprecedented prophylaxis and/or restorative or stabilizing treatment for millions with Alzheimer’s and other central nervous system diseases. Hard to understand just why all of this is so neglected by news writers and reporters. It’s as though Anavex Life Sciences Corp didn’t exist.

Well, in the minds of conventional media people, it doesn’t. Think not? Write a few well-constructed emails to any news entity you’d find appropriate, telling how and why the Anavex story should be reported.

Well, don’t waste your time. (I write with professional competence, but will refrain.) Science and medical news writers continually are confronted with new, revolutionary drugs and treatment protocols for a host of diseases and conditions — none of which have FDA approval for use yet. For them, Anavex can only be just another over the horizon, too good to be true disease treatment option. Publication of just one such story, before there are any useful human outcomes or records (30 folks in Australia certainly don’t count), after which the drug then fails, is the sinking of a writer’s career. Nothing to gain; everything to lose.

The majority of medical “experts,” PhD’s and MD’s, themselves utterly dismiss and neglect the Anavex stuff. Until a bunch of those people start telling science and medical writers that the Anavex story is going to lead to some remarkable outcomes, Anavex will remain a hidden, suppressed story, unworthy of being written about or presented to interested lay readers.

I’ve stated before: Until favorable clinical trial results begin to leak in copious numbers, Anavex will stay hidden from the public.

But, then....